Live Attenuated Influenza Vaccines (laiv) - Vaccines

Relevant Publications

Development of Cross-Reactive Live Attenuated Influenza Vaccine Candidates against Both Lineages of Influenza B Virus.

Issue Release: 2024

Both Humoral and Cellular Immunity Limit the Ability of Live Attenuated Influenza Vaccines to Promote T Cell Responses.

Issue Release: 2024

Reassortment incompetent live attenuated and replicon influenza vaccines provide improved protection against influenza in piglets.

Issue Release: 2024

Characterizing the interactions between influenza and respiratory syncytial viruses and their implications for epidemic control.

Issue Release: 2024

A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein.

Issue Release: 2024

Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity.

Issue Release: 2024

Distinct Functional Humoral Immune Responses Are Induced after Live Attenuated and Inactivated Seasonal Influenza Vaccination.

Issue Release: 2024

Impact of Pre-Existing Immunity and Age on Antibody Responses to Live Attenuated Influenza Vaccine.

Issue Release: 2024

Evaluation of a novel intramuscular prime/intranasal boost vaccination strategy against influenza in the pig model.

Issue Release: 2024

Adverse Effects Related to Paediatric Influenza Vaccination and Its Influence on Vaccination Acceptability. The FLUTETRA Study: A Survey Conducted in the Region of Murcia, Spain.

Issue Release: 2024

Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited by Inactivated and Live Attenuated Vaccines in Children.

Issue Release: 2024

Maternal immunization with distinct influenza vaccine platforms elicits unique antibody profiles that impact the protection of offspring.

Issue Release: 2023

Live attenuated influenza vaccine induces broadly cross-reactive mucosal antibody responses to different influenza strains in tonsils.

Issue Release: 2023

NS1 and PA-X of H1N1/09 influenza virus act in a concerted manner to manipulate the innate immune response of porcine respiratory epithelial cells.

Issue Release: 2023

An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.

Issue Release: 2023

Effectiveness of the quadrivalent live attenuated influenza vaccine against influenza-related hospitalisations and morbidity among children aged 2 to 6 years in Denmark: a nationwide cohort study emulating a target trial.

Issue Release: 2023

[Technical guidelines for seasonal influenza vaccination in China (2023-2024)].

Issue Release: 2023

Generation of a Live Attenuated Influenza A Vaccine Using Chemical-Triggered Intein.

Issue Release: 2023

Truncation of NS1 Protein Enhances T Cell-Mediated Cross-Protection of a Live Attenuated Influenza Vaccine Virus Expressing Wild-Type Nucleoprotein.

Issue Release: 2023

Post-vaccination serum cytokines levels correlate with breakthrough influenza infections.

Issue Release: 2023

Why is Timing Important?

What challenges do vaccination programs face?

How can the public access VSD data and findings?

Why Are Some Vaccines Given in Multiple Doses?

What is Acyclovir?

Why are SIAs Needed?

How is Immunogenicity Measured?

Why Are Pneumococcal Vaccines Important?

Can Vaccines Cause Heart Failure?

What Does "Mimicking the Infection" Mean in Vaccines?

Live Attenuated Influenza Vaccines (laiv) - Vaccines

Relevant Publications

Partnered Content Networks

Relevant Topics